MEDICOMedico Remedies Ltd
Medico Remedies Q1FY27: revenue +81% YoY, PAT +38% as margins compress sharply
pharmaceutical formulations · margin compression · export sales decline
Research Reports
13 Aug 2026
PANACEABIOPANACEA BIOTEC LTD.
Panacea Biotec Q1 FY27: consolidated PAT down 44% YoY on smaller one-off; core swings to profit
vaccines · formulations · margin compression
SUPRIYASupriya Lifescience Ltd
Supriya Lifescience Q1FY27: PAT down 31% YoY on margin squeeze despite 31% revenue growth
pharmaceutical api · margin compression · raw material cost inflation
RAJNISHRajnish Wellness Ltd
Rajnish Wellness Q1 FY27: PAT falls 43% YoY, margins near-zero despite revenue surge
pharma distribution · margin compression · low base growth
IPCALABIPCA LABORATORIES LTD.
IPCA Q1 FY27: consolidated PAT +72% YoY to ₹402 Cr as margins expand, revenue +21%
pharmaceuticals · margin expansion · export growth
LINCOLNLINCOLN PHARMACEUTICALS LTD.
Lincoln Pharma Q1FY27: consolidated PAT up 31% YoY to ₹36.2 Cr as revenue rises 15%
pharmaceuticals · export expansion · other income growth
12 Aug 2026
APOLLOHOSPAPOLLO HOSPITALS ENTERPRISE LTD.
Apollo Hospitals Q1 FY27: consolidated PAT +38% YoY to Rs.610 Cr as revenue grows 21%, margins expand
healthcare services · margin expansion · pharmacy distribution
BLISSGVSBLISS GVS PHARMA LTD.
Bliss GVS Q1FY27: revenue +38% YoY, opex efficiency lifts OPM to 26.8%; PAT +16% YoY
margin expansion · material cost efficiency · open offer
SHALBYShalby Ltd
Shalby Q1FY27: consolidated PAT +37% YoY on lower tax, PBT falls 13%, margins compress
hospital services · medtech segment losses · margin compression
NGLFINENGL FINE-CHEM LTD.
NGL Fine-Chem Q1 FY27: PAT nearly doubles YoY to ₹18.4 Cr, margins expand to 16.7%
pharma intermediates · margin expansion · opm expansion
NATCAPSUQNATURAL CAPSULES LTD.
Natural Capsules Q1FY27: consolidated loss ₹5.7 Cr on API drag; standalone PAT +60% YoY
gelatin capsules · hpmc capsules · api business
SGRLShree Ganesh Remedies Ltd
Shree Ganesh Remedies Q1FY27: consolidated PAT -67% YoY, revenue -42% ahead of Block-7 ramp
api intermediates · specialty chemicals · margin compression
MARKSANSMARKSANS PHARMA LTD.
Marksans Q1 FY27: consolidated PAT jumps 174% YoY to ₹159 Cr as NPM expands to ~19%
margin expansion · acquisition led growth · low base yoy
MAXHEALTHMax Healthcare Institute Ltd
Max Healthcare Q1 Set to Show Mix-Driven Growth vs. Slowdown Headwind
healthcare earnings · hospital capacity · CGHS pricing
11 Aug 2026
AMRUTANJANAMRUTANJAN HEALTH CARE LTD.-$
Amrutanjan Q1 FY27: PAT falls 47% YoY to ₹4.37 Cr as lease-rent hit, hygiene losses widen
fmcg · consumer healthcare · margin compression
LAXMIDENTLLaxmi Dental Ltd
Laxmi Dental Q1FY27: consol PAT +24% YoY to ₹10.3 Cr on margin expansion
dental products · aligners business · margin expansion
INNOVACAPInnova Captab Ltd
Innova Captab Q1 FY27: consolidated PAT +42% YoY to ₹44.1 Cr, revenue +34%, margins widen
pharma cdmo · branded generics · margin expansion
LALPATHLABDr. Lal PathLabs Ltd
Dr. Lal PathLabs: Converging signals of expansion and capital return
diagnostics · expansion · margin
ResearchDeep dive5 minPharma & Healthcare
PREVESTPrevest Denpro Ltd
Prevest Denpro Q1 FY27: consolidated PAT +28% YoY to ₹5.64 Cr, margins expand
dental products · margin expansion · labour code impact
VIYASHSEQUENT SCIENTIFIC LTD.
Viyash Scientific Q1 FY27: consolidated PAT ₹79 Cr, up 115% YoY as margins expand
animal health · margin expansion · amalgamation
ZYDUSLIFEZydus Lifesciences Ltd
Zydus Q1 FY27: Consolidated PAT Falls 36% YoY to ₹940 Cr Despite 22% Revenue Growth
pharmaceuticals · margin compression · acquisition integration
FERMENTAFermenta Biotech Ltd
Fermenta Biotech Q1 FY27: consolidated PAT down 56% YoY as margins nearly halve
vitamin d3 api · bulk drugs chemicals · margin compression
GODAVARIBGodavari Biorefineries Ltd
When a Patent Doubles the Stock Price: Godavari's Oncology Inflection
patent · oncology · intellectual property
ResearchDeep dive6 minPharma & Healthcare
MARKSANSMARKSANS PHARMA LTD.
North America momentum carries into Q1; 15–20% FY27 growth on track
pharma · Q1 FY27 · North America growth
10 Aug 2026
WOCKPHARMAWOCKHARDT LTD.
Wockhardt Q1 FY27: Consolidated PAT swings to ₹107 Cr from ₹108 Cr loss, revenue up 26%
pharmaceuticals · turnaround · consolidated pat
JUBLPHARMAJubilant Pharmova Ltd
Jubilant Pharmova Q1 FY27: PAT Slumps 45% YoY to ₹56 Cr as SPECT Loss Hits Margins
pharma · cdmo · margin compression
INDSWFTLABIND-SWIFT LABORATORIES LTD.
Ind-Swift Labs: consolidated PAT jumps 181% YoY to ₹24.68 Cr on sharp margin expansion
pharmaceuticals · margin expansion · ebitda growth
TARSONSTarsons Products Ltd
Tarsons swings to ₹1.4 Cr consolidated loss in Q1 FY27 despite 20.7% YoY revenue growth
lab plasticware · margin compression · consolidated loss
GLANDGland Pharma Ltd
Gland Pharma Q1 FY27: consolidated PAT up 47% YoY to ₹317 Cr, margins expand to 27%
cdmo growth · margin expansion · us market strength
YATHARTHYatharth Hospital & Trauma Care Services Ltd
Yatharth Q1FY27: consolidated PAT +8% YoY as margins compress despite 51% revenue surge
hospitals · healthcare services · margin compression